Novo Nordisk has announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue tablet.
To be used as a treatment of adults with Type 2 diabetes, this once-daily oral formulation utilises Emisphere Technologies’ proprietary Eligen® SNAC Carrier Technology.
Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.
